EA201290627A1 - Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности - Google Patents
Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточностиInfo
- Publication number
- EA201290627A1 EA201290627A1 EA201290627A EA201290627A EA201290627A1 EA 201290627 A1 EA201290627 A1 EA 201290627A1 EA 201290627 A EA201290627 A EA 201290627A EA 201290627 A EA201290627 A EA 201290627A EA 201290627 A1 EA201290627 A1 EA 201290627A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- kidney damage
- compositions
- methods
- damage
- prediction
- Prior art date
Links
- 210000003734 kidney Anatomy 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000001647 Renal Insufficiency Diseases 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 201000006370 kidney failure Diseases 0.000 title 1
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 abstract 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 abstract 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 abstract 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 abstract 1
- 108010008150 Apolipoprotein B-100 Proteins 0.000 abstract 1
- 108010074051 C-Reactive Protein Proteins 0.000 abstract 1
- 102100032752 C-reactive protein Human genes 0.000 abstract 1
- 102000055006 Calcitonin Human genes 0.000 abstract 1
- 108060001064 Calcitonin Proteins 0.000 abstract 1
- 108010049003 Fibrinogen Proteins 0.000 abstract 1
- 102000008946 Fibrinogen Human genes 0.000 abstract 1
- 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 abstract 1
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 abstract 1
- 102000000743 Interleukin-5 Human genes 0.000 abstract 1
- 108010002616 Interleukin-5 Proteins 0.000 abstract 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 abstract 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 abstract 1
- 102000011721 Matrix Metalloproteinase 12 Human genes 0.000 abstract 1
- 108010076501 Matrix Metalloproteinase 12 Proteins 0.000 abstract 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 abstract 1
- 108010089417 Sex Hormone-Binding Globulin Proteins 0.000 abstract 1
- 102100030758 Sex hormone-binding globulin Human genes 0.000 abstract 1
- 102000002262 Thromboplastin Human genes 0.000 abstract 1
- 108010000499 Thromboplastin Proteins 0.000 abstract 1
- 102000036693 Thrombopoietin Human genes 0.000 abstract 1
- 108010041111 Thrombopoietin Proteins 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 abstract 1
- 229960004015 calcitonin Drugs 0.000 abstract 1
- 239000000104 diagnostic biomarker Substances 0.000 abstract 1
- 229940012952 fibrinogen Drugs 0.000 abstract 1
- 229940100602 interleukin-5 Drugs 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 239000000092 prognostic biomarker Substances 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4737—C-reactive protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/524—Thrombopoietin, i.e. C-MPL ligand
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5409—IL-5
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/585—Calcitonins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70525—ICAM molecules, e.g. CD50, CD54, CD102
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- G01N2333/75—Fibrin; Fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Настоящее изобретение относится к способам и композициям для наблюдения за состоянием, диагностики, прогнозирования и определения схемы лечения субъектов, страдающих повреждением почек или предположительно имеющих повреждение почек. В частности, настоящее изобретение относится к применению одного или более анализов, позволяющих обнаружить маркер повреждения почек, выбранный из группы, состоящей из интерлейкина-5, бета-субъединицы рецептора интерлейкина-6, тканевого фактора, глобулина, связывающего половые гормоны, альфа-2-макроглобулина, аполипопротеина A-I, кальцитонина, тромбопоэтина, С-реактивного белка, молекулы межклеточной адгезии 3, металлоэластазы макрофагов, аполипопротеина В-100 и фибриногена, в качестве диагностических и прогностических биомаркеров повреждения почек.
Applications Claiming Priority (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30196110P | 2010-02-05 | 2010-02-05 | |
| US30203210P | 2010-02-05 | 2010-02-05 | |
| US30203910P | 2010-02-05 | 2010-02-05 | |
| US30198510P | 2010-02-05 | 2010-02-05 | |
| US30204710P | 2010-02-05 | 2010-02-05 | |
| US30197010P | 2010-02-05 | 2010-02-05 | |
| US30204510P | 2010-02-05 | 2010-02-05 | |
| US30204810P | 2010-02-05 | 2010-02-05 | |
| US30199210P | 2010-02-05 | 2010-02-05 | |
| US30201210P | 2010-02-05 | 2010-02-05 | |
| US30200910P | 2010-02-05 | 2010-02-05 | |
| US30198110P | 2010-02-05 | 2010-02-05 | |
| US30201610P | 2010-02-05 | 2010-02-05 | |
| PCT/US2011/023832 WO2011097541A2 (en) | 2010-02-05 | 2011-02-04 | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201290627A1 true EA201290627A1 (ru) | 2013-05-30 |
Family
ID=44356097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201290627A EA201290627A1 (ru) | 2010-02-05 | 2011-02-04 | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20130230871A1 (ru) |
| EP (1) | EP2531622B1 (ru) |
| JP (2) | JP5998055B2 (ru) |
| CN (1) | CN102884205B (ru) |
| AU (1) | AU2011213686B2 (ru) |
| CA (1) | CA2788829A1 (ru) |
| EA (1) | EA201290627A1 (ru) |
| HK (1) | HK1174367A1 (ru) |
| MX (1) | MX339765B (ru) |
| NZ (1) | NZ601648A (ru) |
| WO (1) | WO2011097541A2 (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012078736A2 (en) * | 2010-12-09 | 2012-06-14 | The Brigham And Women's Hospital, Inc. | Fibrinogen and kidney damage |
| KR20160142390A (ko) | 2014-04-09 | 2016-12-12 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 면역평가 및 이식거부의 예측을 위한 단백질 바이오마커 |
| ES2792227T3 (es) | 2014-09-26 | 2020-11-10 | Somalogic Inc | Predicción de evento de riesgo cardiovascular y usos de la misma |
| US11244760B2 (en) | 2015-06-25 | 2022-02-08 | Karydo Therapeutix, Inc. | Prediction device based on inter-organ cross talk system |
| GB201511207D0 (en) * | 2015-06-25 | 2015-08-12 | Xvivo Perfusion Ab | Isolated organ evaluation and treatment |
| WO2017170803A1 (ja) | 2016-03-29 | 2017-10-05 | 株式会社国際電気通信基礎技術研究所 | 医薬組成物又は食品組成物、及び有効成分の体内での効果の評価方法 |
| CN114686584A (zh) * | 2016-03-29 | 2022-07-01 | 无限生物制药公司 | 用以预防或治疗肾脏疾病的活性组分的候选物质的筛选装置和筛选方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5939272A (en) | 1989-01-10 | 1999-08-17 | Biosite Diagnostics Incorporated | Non-competitive threshold ligand-receptor assays |
| US5028535A (en) | 1989-01-10 | 1991-07-02 | Biosite Diagnostics, Inc. | Threshold ligand-receptor assay |
| JPH02275359A (ja) * | 1989-04-18 | 1990-11-09 | Teijin Ltd | 腎疾患の診断方法、診断試薬およびキット |
| US5922615A (en) | 1990-03-12 | 1999-07-13 | Biosite Diagnostics Incorporated | Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network |
| CA2072758A1 (en) | 1990-09-14 | 1992-03-15 | Kenneth Francis Buechler | Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays |
| US5955377A (en) | 1991-02-11 | 1999-09-21 | Biostar, Inc. | Methods and kits for the amplification of thin film based assays |
| EP0585310B1 (en) | 1991-04-10 | 1999-03-17 | Biosite Diagnostics Inc. | Crosstalk inhibitors and their uses |
| ATE195808T1 (de) | 1991-04-12 | 2000-09-15 | Biosite Diagnostics Inc | Neue konjugate und testverfahren für die gleichzeitige bestimmung von multiplen liganden |
| US6143576A (en) | 1992-05-21 | 2000-11-07 | Biosite Diagnostics, Inc. | Non-porous diagnostic devices for the controlled movement of reagents |
| US5885527A (en) | 1992-05-21 | 1999-03-23 | Biosite Diagnostics, Inc. | Diagnostic devices and apparatus for the controlled movement of reagents without membrances |
| US5494829A (en) | 1992-07-31 | 1996-02-27 | Biostar, Inc. | Devices and methods for detection of an analyte based upon light interference |
| US5824799A (en) | 1993-09-24 | 1998-10-20 | Biosite Diagnostics Incorporated | Hybrid phthalocyanine derivatives and their uses |
| US6113855A (en) | 1996-11-15 | 2000-09-05 | Biosite Diagnostics, Inc. | Devices comprising multiple capillarity inducing surfaces |
| US5947124A (en) | 1997-03-11 | 1999-09-07 | Biosite Diagnostics Incorporated | Diagnostic for determining the time of a heart attack |
| US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| US20040253637A1 (en) * | 2001-04-13 | 2004-12-16 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
| FR2872579B1 (fr) * | 2004-06-30 | 2006-11-24 | Pasteur Institut | Detection de la tuberculose et de l'infection par mycobacterium tuberculosis a l'aide de hbha |
| AU2006210794A1 (en) * | 2005-02-01 | 2006-08-10 | Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services | Biomarkers for tissue status |
| US7608413B1 (en) * | 2005-03-25 | 2009-10-27 | Celera Corporation | Kidney disease targets and uses thereof |
| US7623910B2 (en) * | 2006-03-10 | 2009-11-24 | University Of Rochester | ECG-based differentiation of LQT1 and LQT2 mutation |
| WO2008084331A2 (en) * | 2006-06-21 | 2008-07-17 | Hopitaux Universitaires De Geneve | Biomarkers for renal disorders |
| US9012162B2 (en) * | 2006-09-08 | 2015-04-21 | The Chancellor, Masters And Scholars Of The University Of Oxford | Clinical diagnosis of hepatic fibrosis using a novel panel of human serum protein biomarkers |
| EP2257813A4 (en) * | 2008-03-12 | 2011-11-02 | Univ Columbia | NGAL WITH HIGH MOLECULAR WEIGHT AS BIOMARKER FOR CHRONIC KIDNEY DISEASE |
-
2011
- 2011-02-04 JP JP2012552129A patent/JP5998055B2/ja not_active Expired - Fee Related
- 2011-02-04 US US13/577,244 patent/US20130230871A1/en not_active Abandoned
- 2011-02-04 EP EP11740470.7A patent/EP2531622B1/en not_active Not-in-force
- 2011-02-04 MX MX2012008955A patent/MX339765B/es active IP Right Grant
- 2011-02-04 NZ NZ601648A patent/NZ601648A/en not_active IP Right Cessation
- 2011-02-04 CA CA2788829A patent/CA2788829A1/en not_active Abandoned
- 2011-02-04 EA EA201290627A patent/EA201290627A1/ru unknown
- 2011-02-04 AU AU2011213686A patent/AU2011213686B2/en not_active Ceased
- 2011-02-04 WO PCT/US2011/023832 patent/WO2011097541A2/en active Application Filing
- 2011-02-04 CN CN201180015316.2A patent/CN102884205B/zh not_active Expired - Fee Related
-
2013
- 2013-02-08 HK HK13101784.3A patent/HK1174367A1/zh not_active IP Right Cessation
-
2015
- 2015-08-12 JP JP2015159649A patent/JP6186400B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| MX339765B (es) | 2016-06-08 |
| CN102884205A (zh) | 2013-01-16 |
| AU2011213686A1 (en) | 2012-08-30 |
| EP2531622B1 (en) | 2016-04-06 |
| CA2788829A1 (en) | 2011-08-11 |
| JP6186400B2 (ja) | 2017-08-23 |
| WO2011097541A2 (en) | 2011-08-11 |
| AU2011213686B2 (en) | 2015-11-12 |
| NZ601648A (en) | 2015-05-29 |
| WO2011097541A3 (en) | 2011-11-10 |
| CN102884205B (zh) | 2016-05-04 |
| MX2012008955A (es) | 2012-11-23 |
| EP2531622A4 (en) | 2013-07-17 |
| US20130230871A1 (en) | 2013-09-05 |
| JP5998055B2 (ja) | 2016-09-28 |
| JP2016006430A (ja) | 2016-01-14 |
| HK1174367A1 (zh) | 2013-06-07 |
| JP2013519866A (ja) | 2013-05-30 |
| EP2531622A2 (en) | 2012-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201290627A1 (ru) | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности | |
| EA201290629A1 (ru) | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности | |
| EA201290387A1 (ru) | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности | |
| van der Velde et al. | Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH | |
| JP6126186B2 (ja) | 腎損傷および腎不全の診断および予後のための方法および組成物 | |
| ES2926197T3 (es) | Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal | |
| EA201290711A1 (ru) | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности | |
| NZ630277A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| Ford et al. | FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease–mineral bone disorder and the heart | |
| NZ592488A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| EA201290056A1 (ru) | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности | |
| EA201490105A1 (ru) | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности | |
| WO2008061149A3 (en) | Methods and compositions for diagnosis and prognosis of renal artery stenosis | |
| JP2013541706A5 (ru) | ||
| ES2907551T3 (es) | Procedimientos y composiciones para el diagnóstico y pronóstico de una lesión renal y una insuficiencia renal | |
| EP2506016A2 (en) | Diagnostic method for detecting acute kidney injury using heat shock protein 72 as a sensitive biomarker | |
| JP2022091846A (ja) | Ｃ－ｃモチーフケモカインリガンド１４の測定に基づく腎損傷および腎不全の評価および処置のための方法および組成物 | |
| Wang et al. | Risk factors for mortality in patients with septic acute kidney injury in intensive care units in Beijing, China: a multicenter prospective observational study | |
| RU2013138721A (ru) | Способы и наборы для прогнозирования риска дыхательной недостаточности, почечной недостаточности или тромбопении у пациента, страдающего сепсисом, путем измерения уровней эндокана в крови | |
| WO2012175672A3 (en) | Diagnosis and/or prognosis of parkinson's disease dementia | |
| SI3171174T1 (en) | Lactoferrin for use in the diagnosis or prognosis of Alzheimer's disease | |
| PE20120592A1 (es) | Metodo con biomarcadores para el seguimiento de un tratamiento | |
| Lee et al. | Comparison of two creatinine-based equations for predicting decline in renal function in type 2 diabetic patients with nephropathy in a Korean population | |
| Arroyo et al. | High-sensitivity troponin T levels in kidney transplant recipients | |
| WO2012167887A8 (en) | Diagnostic use of prosomatostatin |